Introduction: Patients with hidradenitis suppurativa (HS) experience a 10-year diagnosis delay, on average. Accordingly, time to diagnosis represents one of the greatest unmet needs in HS, which to date has not been adequately addressed. A general lack of awareness about HS in the medical community and a notable heterogeneity in clinical presentation, which is most often confused with cutaneous abscess (CA), forms the basis of poor disease recognition and diagnosis delay. Our objective was to develop and validate a prediction model for diagnosis of HS versus site-specific CA. Methods: We performed a cross-sectional study in which the model was developed using a large clinical database and externally validated using a sample of clinical records at Penn State Health. Prediction model discrimination and calibration were evaluated using the c-statistic, calibration intercept/slope, and a flexible calibration curve. Results: Variable selection identified 15 predictors, 7 of which remained after model simplification. The following characteristics were predictive of HS relative to site-specific CA: female sex, increasing age up to 44 years, African American race, race other than white or African American, increasing body mass index, polycystic ovarian syndrome, and acne. The c-statistic of the 7-variable model in validation was 0.77 (95% CI: 0.73–0.80). Calibration intercept and slope were 0.29 (95% CI: 0.14, 0.43) and 1.09 (95% CI: 0.90, 1.28). Conclusion: Clinical characteristics can predict diagnosis of HS over CA in practice without reliance on a specialty-specific examination to identify disease and potentially reduce diagnosis delay.

1.
Garg
A
,
Neuren
E
,
Cha
D
,
Kirby
JS
,
Ingram
JR
,
Jemec
GBE
, et al
.
Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) Project
.
J Am Acad Dermatol
.
2020
;
82
(
2
):
366
76
.
2.
Kokolakis
G
,
Wolk
K
,
Schneider-Burrus
S
,
Kalus
S
,
Barbus
S
,
Gomis-Kleindienst
S
, et al
.
Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system
.
Dermatology
.
2020
;
236
(
5
):
421
30
.
3.
Garg
A
,
Reddy
S
,
Kirby
J
,
Strunk
A
.
Development and validation of HSCAPS-1: a clinical decision support tool for diagnosis of hidradenitis suppurativa over cutaneous abscess
.
Dermatology
.
2021
;
237
(
5
):
719
26
.
4.
Moons
KG
,
Altman
DG
,
Reitsma
JB
,
Ioannidis
JPA
,
Macaskill
P
,
Steyerberg
EW
, et al
.
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration
.
Ann Intern Med
.
2015
;
162
(
1
):
W1
73
.
5.
Merative [Internet]
.
Real-world evidence solutions for life sciences
. [cited 2024 Oct 25]. Available from: https://www.merative.com/content/dam/merative/documents/brief/real-world-evidence-solution-brief.pdf
6.
Garg
A
,
Malviya
N
,
Strunk
A
,
Wright
S
,
Alavi
A
,
Alhusayen
R
, et al
.
Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations
.
J Am Acad Dermatol
.
2022
;
86
(
5
):
1092
101
.
7.
Wood
AM
,
White
IR
,
Royston
P
.
How should variable selection be performed with multiply imputed data
.
Stat Med
.
2008
;
27
(
17
):
3227
46
.
8.
Ambler
G
,
Brady
AR
,
Royston
P
.
Simplifying a prognostic model: a simulation study based on clinical data
.
Stat Med
.
2002
;
21
(
24
):
3803
22
.
9.
Janssen
KJ
,
Moons
KG
,
Kalkman
CJ
,
Grobbee
DE
,
Vergouwe
Y
.
Updating methods improved the performance of a clinical prediction model in new patients
.
J Clin Epidemiol
.
2008
;
61
(
1
):
76
86
.
10.
Van Calster
B
,
McLernon
DJ
,
van Smeden
M
,
Wynants
L
,
Steyerberg
EW
,
Topic Group “Evaluating diagnostic tests and prediction models” of the STRATOS initiative
.
Calibration: the Achilles heel of predictive analytics
.
BMC Med
.
2019
;
17
(
1
):
230
.
11.
Garg
A
,
Kirby
JS
,
Lavian
J
,
Lin
G
,
Strunk
A
.
Sex- and Age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States
.
JAMA Dermatol
.
2017
;
153
(
8
):
760
4
.
12.
Garg
A
,
Lavian
J
,
Lin
G
,
Strunk
A
,
Alloo
A
.
Incidence of hidradenitis suppurativa in the United States: a sex-and age-adjusted population analysis
.
J Am Acad Dermatol
.
2017
;
77
(
1
):
118
22
.
13.
Cosmatos
I
,
Matcho
A
,
Weinstein
R
,
Montgomery
MO
,
Stang
P
.
Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
.
J Am Acad Dermatol
.
2013
;
68
(
3
):
412
9
.
14.
Shahi
V
,
Alikhan
A
,
Vazquez
BG
,
Weaver
AL
,
Davis
MD
.
Prevalence of hidradenitis suppurativa: a population-based study in Olmsted County, Minnesota
.
Dermatology
.
2014
;
229
(
2
):
154
8
.
15.
Edigin
E
,
Kaul
S
,
Eseaton
PO
,
Albrecht
J
.
Racial and ethnic distribution of patients hospitalized with hidradenitis suppurativa, 2008-2018
.
JAMA Dermatol
.
2021
;
157
(
9
):
1125
7
.
16.
Wright
S
,
Strunk
A
,
Garg
A
.
Trends in body mass index before and after diagnosis of hidradenitis suppurativa
.
Br J Dermatol
.
2021
;
185
(
1
):
74
9
.
17.
Gold
DA
,
Reeder
VJ
,
Mahan
MG
,
Hamzavi
IH
.
The prevalence of metabolic syndrome in patients with hidradenitis suppurativa
.
J Am Acad Dermatol
.
2014
;
70
(
4
):
699
703
.
18.
Wertenteil
S
,
Strunk
A
,
Garg
A
.
Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa
.
J Am Acad Dermatol
.
2019
;
80
(
5
):
e131
2
.
19.
Kimball
AB
,
Sundaram
M
,
Gauthier
G
,
Guérin
A
,
Pivneva
I
,
Singh
R
, et al
.
The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis
.
Dermatol Ther
.
2018
;
8
(
4
):
557
69
.
20.
Garg
A
,
Neuren
E
,
Strunk
A
.
Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States
.
J Invest Dermatol
.
2018
;
138
(
6
):
1288
92
.
21.
Shlyankevich
J
,
Chen
AJ
,
Kim
GE
,
Kimball
AB
.
Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis
.
J Am Acad Dermatol
.
2014
;
71
(
6
):
1144
50
.
22.
Garg
A
,
Birabaharan
M
,
Strunk
A
.
Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States
.
J Am Acad Dermatol
.
2018
;
79
(
1
):
71
6
.
23.
Shah
BR
,
Hux
JE
.
Quantifying the risk of infectious diseases for people with diabetes
.
Diabetes Care
.
2003
;
26
(
2
):
510
3
.
24.
Muller
LM
,
Gorter
KJ
,
Hak
E
,
Goudzwaard
WL
,
Schellevis
FG
,
Hoepelman
AI
, et al
.
Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus
.
Clin Infect Dis
.
2005
;
41
(
3
):
281
8
.
25.
Ray
GT
,
Suaya
JA
,
Baxter
R
.
Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a US population: a retrospective population-based study
.
BMC Infect Dis
.
2013
;
13
:
252
.
You do not currently have access to this content.